Use of a Unique Mobile Medical Asset in COVID Monoclonal Antibody Treatment
The COVID-19 pandemic and the subsequent surge of patients presented to emergency departments has forever changed the paradigm of delivering emergency care. The highly infectious nature of the 2019 Novel Coronavirus, or COVID-19, mandated strict environmental changes, novel patient care, and flexibl...
Main Authors: | Herman Morchel, David Clark, Leighanne Buenvenida, Chinwe Ogedegbe |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Healthcare |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9032/9/8/990 |
Similar Items
-
Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis
by: Yu-Lin Tai, et al.
Published: (2023-05-01) -
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial
by: Himanshu P. Upadhyaya, et al.
Published: (2023-06-01) -
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern
by: Fulvia Mazzaferri, et al.
Published: (2022-11-01) -
The Therapeutic Monoclonal Antibody Bamlanivimab Does Not Enhance SARS-CoV-2 Infection by FcR-Mediated Mechanisms
by: Robert W. Cross, et al.
Published: (2023-11-01) -
Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy
by: Daniele Focosi, et al.
Published: (2022-07-01)